Focus: Centessa Pharmaceuticals is an umbrella company that acquires and develops drug programs, operating as a Lilly-owned entity focused on neurology and rare disease therapeutics. The company functions as an acquisition platform consolidating multiple pipeline programs across diverse therapeutic areas.
Profile data last refreshed 17h ago · AI intelligence enriched 4w ago
Cooling — net -18 jobs in 30d
2 added, 20 removed. Slower than typical.
Best suited for scientists and operations professionals seeking exposure to multi-program pipeline execution within a stable, Lilly-backed structure; less ideal for those prioritizing revenue-stage stability or commercial experience.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Centessa Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Centessa Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly - Pharmaceutical Executive
InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly Pharmaceutical Executive
Nxera Pharma wins $8.6m milestone payment from Lilly-owned Centessa Pharmaceuticals - Business Weekly
Nxera Pharma wins $8.6m milestone payment from Lilly-owned Centessa Pharmaceuticals Business Weekly
Nxera Pharma to Receive $8.6 Million Milestone Payment from - GlobeNewswire
Nxera Pharma to Receive $8.6 Million Milestone Payment from GlobeNewswire
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress - Yahoo Finance
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress Yahoo Finance
Lilly Completes Centessa Acquisition to Expand Sleep Disorder Drug Pipeline - citybiz
Lilly Completes Centessa Acquisition to Expand Sleep Disorder Drug Pipeline citybiz
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders - PR Newswire
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders PR Newswire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Coagulation and platelet biology at the intersection of health and disease: illustrated capsules of the 11th Symposium on Hemostasis at the University of North Carolina.
Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo